Company intelligence / Profile preview

Legend Advanced Biomedicinals

Somerset, New Jersey, United States

Ownership: Private
Employees: ~3500
Development stage: Other

Overview

Legend Biotech is a global commercial-stage cell therapy company pioneering autologous CAR-T cell therapies for hematologic malignancies, especially multiple myeloma. Its flagship product, ciltacabtagene autoleucel (CARVYKTI®), is FDA- and EMA-approved for relapsed/refractory multiple myeloma, with additional cell therapy programs advancing through early-phase clinical trials for hematologic malignancies and solid tumors. Recent data show strong clinical efficacy, including five-year survival results in multiple myeloma.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyNK cell therapyGamma-delta T cell therapyNanobodyFusion proteinAutologous CAR-TUniversal CAR-T
Industry: Biotech

Partnerships

Janssen Biotech (Johnson & Johnson Pharmaceuticals)

Beyond the preview

Go deeper on Legend Advanced Biomedicinals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend Advanced Biomedicinals.

Explore the full profile